Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CAH

DatePrice TargetRatingAnalyst
2/5/2025$140.00 → $150.00Hold → Buy
Jefferies
1/8/2025$130.00 → $144.00Hold → Buy
TD Cowen
1/7/2025$140.00In-line → Outperform
Evercore ISI
1/6/2025$132.00 → $145.00Neutral → Buy
BofA Securities
12/13/2024$101.00 → $127.00Underweight → Equal Weight
Wells Fargo
12/4/2024$139.00Outperform
Mizuho
2/26/2024$125.00Outperform
Leerink Partners
2/9/2024Hold → Buy
Argus
More analyst ratings

$CAH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2025 on May 1

    DUBLIN, Ohio, March 25, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) plans to release third-quarter financial results for its fiscal year 2025 on May 1, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months. About Cardinal Health Cardinal Hea

    $CAH
    Other Pharmaceuticals
    Health Care
  • Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CAH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CAH
SEC Filings

See more

$CAH
Leadership Updates

Live Leadership Updates

See more
  • Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    $CAH
    Other Pharmaceuticals
    Health Care
  • RPM Announces Appointment of Three New Board Members

    RPM International Inc. (NYSE:RPM) today announced the appointment of three individuals, Craig S. Morford, Christopher L. Mapes and Julie A. Beck, to its board of directors. These appointments reflect RPM's ongoing commitment to expanding the expertise, diversity and leadership capabilities of its board as the company continues to drive long-term growth and shareholder value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113146614/en/Christopher L. Mapes (Photo: Business Wire) The appointments of Mr. Morford and Mr. Mapes are effective immediately, and Ms. Beck's term is set to commence on April 7, 2025. With these additions,

    $AOS
    $CAH
    $LECO
    $NDSN
    Consumer Electronics/Appliances
    Consumer Discretionary
    Other Pharmaceuticals
    Health Care
  • Bob Azelby to join Cardinal Health Board of Directors

    DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmac

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Financials

Live finance-specific insights

See more
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nucle

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

    Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expirationGAAP1 operating earnings were $549 million; GAAP diluted EPS was $1.65Non-GAAP operating earnings increased 9% to $635 million, driven by the Pharmaceutical and Specialty Solutions segment; non-GAAP diluted EPS increased 2% to $1.93Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.85 to $8.00, from $7.75 to $7.90Company announces the completion of its acquisition of 73% ownership of GI AllianceDUBLIN, Ohio, Jan. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported second quarter fiscal year 2025 revenues of $55.3 billion, a decrea

    $CAH
    Other Pharmaceuticals
    Health Care
  • Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 5, 2024 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on January 15, 2025 to shareholders of record at the close of business on January 2, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    $CAH
    Other Pharmaceuticals
    Health Care

$CAH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more